Cargando…

SEOM clinical guideline for the management of cutaneous melanoma (2020)

Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and...

Descripción completa

Detalles Bibliográficos
Autores principales: Majem, M., Manzano, J. L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E., de la Cruz-Merino, L., Espinosa, E., Gonzalez-Cao, M., Berrocal, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998/
https://www.ncbi.nlm.nih.gov/pubmed/33651321
http://dx.doi.org/10.1007/s12094-020-02539-9
_version_ 1783680941343899648
author Majem, M.
Manzano, J. L.
Marquez-Rodas, I.
Mujika, K.
Muñoz-Couselo, E.
Pérez-Ruiz, E.
de la Cruz-Merino, L.
Espinosa, E.
Gonzalez-Cao, M.
Berrocal, A.
author_facet Majem, M.
Manzano, J. L.
Marquez-Rodas, I.
Mujika, K.
Muñoz-Couselo, E.
Pérez-Ruiz, E.
de la Cruz-Merino, L.
Espinosa, E.
Gonzalez-Cao, M.
Berrocal, A.
author_sort Majem, M.
collection PubMed
description Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
format Online
Article
Text
id pubmed-8057998
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80579982021-05-05 SEOM clinical guideline for the management of cutaneous melanoma (2020) Majem, M. Manzano, J. L. Marquez-Rodas, I. Mujika, K. Muñoz-Couselo, E. Pérez-Ruiz, E. de la Cruz-Merino, L. Espinosa, E. Gonzalez-Cao, M. Berrocal, A. Clin Transl Oncol Clinical Guides in Oncology Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. Springer International Publishing 2021-03-02 2021 /pmc/articles/PMC8057998/ /pubmed/33651321 http://dx.doi.org/10.1007/s12094-020-02539-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Guides in Oncology
Majem, M.
Manzano, J. L.
Marquez-Rodas, I.
Mujika, K.
Muñoz-Couselo, E.
Pérez-Ruiz, E.
de la Cruz-Merino, L.
Espinosa, E.
Gonzalez-Cao, M.
Berrocal, A.
SEOM clinical guideline for the management of cutaneous melanoma (2020)
title SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_full SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_fullStr SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_full_unstemmed SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_short SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_sort seom clinical guideline for the management of cutaneous melanoma (2020)
topic Clinical Guides in Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998/
https://www.ncbi.nlm.nih.gov/pubmed/33651321
http://dx.doi.org/10.1007/s12094-020-02539-9
work_keys_str_mv AT majemm seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT manzanojl seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT marquezrodasi seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT mujikak seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT munozcouseloe seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT perezruize seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT delacruzmerinol seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT espinosae seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT gonzalezcaom seomclinicalguidelineforthemanagementofcutaneousmelanoma2020
AT berrocala seomclinicalguidelineforthemanagementofcutaneousmelanoma2020